Chapter 19: Antiarrhythmics

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical treatment, there is this expectation of a really straightforward cause and effect.

Right, like a linear satisfying model.

Exactly.

Absolutely.

I mean, you have an infection, you take an antibiotic, bacteria die, problem solved.

It's neat.

It's tidy.

Yeah.

But step into the world of cardiac pharmacology and suddenly that logic just gets turned entirely upside down.

We are looking at a therapeutic landscape that is, well, it's a massive paradox.

Oh, absolutely.

It is the literal definition of a double edged sword.

Because the very drugs designed to fix an irregular heartbeat are notoriously famous for actually causing them.

Yeah, it's wild.

It is.

And, you know, if you are a college student studying for your pharmacology exams right now, you already know the stakes here are incredibly high.

So today we are doing a deep dive into chapter 19 of Lippincott's illustrated reviews on pharmacology.

The antiarrhythmics chapter.

Right.

Our mission today is to figure out exactly why this paradox exists and how to navigate it without getting completely lost in the side effects.

And to really understand how we fix these chaotic rhythms, we first have to understand what makes a heartbeat go rogue in the first place.

Yeah, the baseline physiology.

Exactly.

Then we can look at the four specific physiological breaks, basically, that we can apply to force the system back into a normal rhythm.

And then we'll cover a few weird outliers at the end.

Perfect.

So let's start with that baseline.

The textbook draws this really sharp contract right away between skeletal muscle and cardiac muscle.

Skeletal muscle is basically like a puppet.

It just sits there, completely inert,

waiting for a nervous system string to pull it before it does anything.

But the heart operates on an entirely different level through this property called automaticity.

Automaticity.

Yeah.

It intrinsically generates its own rhythmic action potentials.

It doesn't need any external nervous system stimulus whatsoever.

Which is amazing, honestly.

It is.

And it's all thanks to these highly specialized pacemaker cells.

And the key to this, the specific part of the cardiac cycle the text really hones in is phase four.

Yes.

Phase four is crucial.

So if you visualize a graph tracking the electrical charge of these cells over time, phase four is that slow, spontaneous upward slope.

OK.

So it's drifting upward.

Right.

During diastole, when the heart is theoretically resting and filling with blood,

there is this slow inward positive current.

It's carried by sodium and calcium ions.

So the inside of the cell is slowly getting more and more positive.

Exactly.

Until it hits a critical threshold.

Right.

And the moment it hits that line, bam, it fires.

And that upward slope is steepest at the sinoatrial node, right?

The SA node.

Right.

Which means it hits the threshold and fires the fastest.

Which naturally dictates the pace for the entire heart.

I mean, the fastest one wins.

Exactly.

And from the SA node, the electrical impulse normally travels this very specific orderly route.

It goes down to the atrioventricular node, the AV node.

Then through the bundle of his and finally spreading out through the Purkinje system to physically squeeze the ventricles.

OK, let's unpack this.

Because what actually causes that perfectly timed, you know, miraculous system to glitch out?

Well, the chapter details two main culprits.

First is abnormal automaticity.

Meaning something else is trying to take over.

Right.

This happens when other sites in the heart get irritated or damaged,

say maybe from ischemia.

The lack of oxygen.

Yeah.

And they decide they want to be the pacemaker now.

So they start firing faster than the SA node, creating these competing stimuli.

That's like a microscopic mutiny.

That's a great way to put it.

And to stop that mutiny, our drugs have to step in and block those sodium or calcium channels to literally flatten out that phase four slope.

So they decrease the angle of the slope.

Or they raise the threshold needed to fire.

Either way, the drugs force those rogue mutated cells to slow down their discharge frequency.

Until the SA node can basically regain control of the ship.

Precisely.

Now that's the first glitch.

The second one, which the text notes is actually the most common cause of arrhythmias, is called reentry.

Reentry.

Okay.

I like to picture this one like a traffic roundabout.

Oh yeah.

The roundabout analogy is perfect.

So imagine an electrical impulse is driving down a normal bifurcated pathway, like a fork in the road.

But one of the exits is blocked because of some myocardial injury or maybe a prolonged recovery time.

So you now have a unidirectional block.

Right.

The electrical car, so to speak, cannot go forward down that damaged path.

Exactly.

So instead of exiting the pathway,

the signal travels backward up the other side.

It reenters the pathway, creating this chaotic continuous loop.

Like a short circuit, a roundabout nobody can get off of.

Exactly.

It just keeps spinning.

And how the antiarrhythmic agents break that loop is really fascinating.

What do they do?

To stop a reentry circuit, the drugs either slow down the conduction velocity.

Making the car drive much slower through the roundabout.

Right.

Or they increase the tissue's refractory period, which is the mandatory time it takes for the tissue to reset before it can fire again.

Oh, so they basically convert that one -way street closure into a total roadblock.

Yes.

They turn a unidirectional block into a bidirectional block.

The chaotic loop hits a dead end, and that shuts down the short circuit entirely.

OK, so if those are the mechanisms of the glitch, what are the tools we actually have to fix them?

The text uses the Vaughan Williams classification, right?

It groups our tools into four main classes based on where they hit the action potential.

Think of these as our four different types of breaks.

Exactly.

Class 1 targets sodium channels.

Class 2 targets beta -adrenergic receptors.

Class 3 targets potassium channels.

And Class 4 targets calcium channels.

So sodium, beta, potassium, calcium.

But before we even touch the first break, we really have to talk about that massive grave warning we mentioned earlier.

The proarrhythmic danger, yes.

It is literally the shadow hanging over this entire chapter.

It really is.

Many of these drugs, particularly those that block potassium channels, end up widening the action potential.

And on an EKG, that widening visibly shows up as a prolonged QT interval.

Right.

And stretching out that QT interval is not just some minor incidental finding on a chart that you can ignore.

No, it's a huge red flag.

It significantly increases the risk of a life -threatening ventricular tachyarrhythmia called torsades de pointes.

Torsades de pointes.

Yeah.

It's this chaotic, twisting heart rhythm that can very quickly become fatal.

You have to be incredibly vigilant, especially when a patient might be on other medications that also prolong the QT interval.

Like certain macrolide antibiotics or antipsychotics?

Exactly.

If you mix them, you are just stacking the deck for a catastrophic event.

Okay, so keeping that danger in mind, let's look at that first break.

Class I, the sodium channel blockers.

These affect phase zero, which is the initial rapid upward spike of the heartbeat.

And they also affect phase three.

And there's a really vital concept here called used dependence.

I always picture these drugs as bouncers at a club.

A bouncer?

How so?

Well, they completely ignore the people walking at a normal pace, but they immediately tackle anyone trying to sprint through the front door.

Oh, that captures used dependence perfectly.

Yeah, these class I drugs bind much more rapidly to sodium channels that are actively open or recently inactivated.

Compared to channels that are just fully at rest.

Right.

So they really only tackle the cells firing out of control.

Which allows the drug to target the abnormally fast ectopic pacemaker cells without completely paralyzing the normal slower beating of the rest of the heart.

Exactly.

Now, class I is actually subdivided into three groups based on how they affect the duration of the action potential.

Let's start with class IA.

That's quinidine, prokanymide, and disapiramide.

Right.

If you visualize a heart monitor, these drugs take that sharp upward phase zero spike and kind of tilt it sideways, slowing the influx of sodium.

But they also prolong the overall action potential, right?

They do, because they have some secondary class three potassium blocking activity too.

Meaning they carry that risk of prolonging the QT interval we just warned about.

Exactly.

And they're binding kinetics.

How fast they attach and detach from the sodium channels are intermediate.

Now, there are some heavily tested clinical pearls here for the exam.

Oh, absolutely.

Let's say a patient taking one of these complaints of severe dry mouth, blurred vision, and urinary hesitancy.

That is the classic anticholinergic profile of disapiramide.

And it is so important to understand why that happens.

Because disapiramide isn't just blocking sodium channels in the heart.

Right.

It aggressively antagonizes muscarinic receptors systemically.

Right.

So you lose that parasympathetic tone, leading to those severe drying out effects.

And the text says disapiramide is the worst offender in the IA group for this.

It definitely is.

Meanwhile, quinidine is famous for causing something called synchonism at large doses.

Synchonism.

That's tinnitus, blurred vision, headache, and psychosis, right?

Yeah.

It is a very specific toxicity profile that is totally unique to quinidine.

Okay.

Then there is prokainamide.

Prokainamide is a pharmacokinetic wild card, honestly.

How so?

Well, it is acetylated in the liver into an active metabolite called NAPPA.

And NAPPA actually acts like a class 3 drug.

Oh, meaning it predominantly blocks potassium.

Right.

And because NAPPA is cleared entirely by the kidneys, any patient with renal dysfunction is going to accumulate it rapidly.

Spiking their risk for toxicity.

Okay.

So if class IA drugs tilt the spike and stretch the potential, what happens when we look at class IB?

That's lidocaine and mexalatine.

These actually shorten phase 3 repolarization.

And their binding kinetics are lightning fast.

They rapidly associate and dissociate from the sodium channels.

Which means they are really only effective when the cardiac cell is depolarizing extremely fast.

Right.

They essentially ignore atrial rhythms entirely because they simply aren't fast enough.

So they're targeted.

Very.

Class IB drugs are highly specific for treating ventricular arrhythmias, like ventricular tachycardia.

Clinically though, lidocaine and mexalatine are handed very differently, aren't they?

Oh yeah.

Lidocaine has to be given IV because it undergoes massive first pass metabolism in the liver.

Meaning if a patient swallowed it as a pill, the liver would destroy almost all of it before it ever reached the systemic circulation.

Exactly.

And when giving it IV, you have to monitor for early lidocaine toxicity, which actually presents as central nervous system effects.

Oh right.

The classic sign is nystagmus, that involuntary rapid eye movement.

Yeah.

Along with drowsiness or slurred speech.

You have to watch for that closely.

And mexalatine, however, is formulated as an oral drug.

It is.

But it has a notorious side effect,

severe dyspepsia.

It irritates the GI tract so badly that the heartburn and upset stomach are often the limiting factors for patients even trying to take it.

Yeah, they just can't tolerate it.

Which leaves us with class IC, fluconide, and propafenone.

And these drugs drastically, markedly slow that phase zero upstroke.

Because they dissociate from the sodium channels incredibly slowly.

Their effects are prominent, even at normal heart rates.

But here's where it gets really interesting.

There is a massive clinical red flag here.

Huge red flag due to their negative inotropic effects.

Meaning they severely weaken the actual mechanical squeezing force of the heart muscle.

Right.

Combined with their immense prurimnic risks, class IC drugs must be absolutely avoided in patients with structural heart disease.

This is such a classic exam trap.

It really is.

Like, if a clinician wants to start fluconide, and the multiple choice patient has hypertension,

left ventricular hypertrophy, coronary artery disease, and heart failure.

The only condition on that list that allows fluconide is hypertension.

Exactly.

If they have structural changes to the heart muscle from the other three, fluconide is totally off the table because their weakened heart simply cannot handle the negative inotropy.

Spot on.

Oh, and propafenone.

Yeah.

It actually has weak beta blocking properties, so it can trigger bronchospasm.

So keep it away from asthmatics.

Exactly.

Keep it far away.

So if class on drugs are the bouncer stopping the rapid influx of sodium during that initial spike, what happens if the problem isn't the spike itself, but the resting heart rate creeping up too fast?

That brings us perfectly to class two, the beta blockers.

We are moving away from phase zero now and focusing purely on phase four.

Right.

By blocking beta adrenergic receptors, these drugs diminish that slow, spontaneous depolarization we talked about at the very beginning.

So they depress automaticity and slow down conduction through the AV node.

Yeah.

They basically put a physiological governor on the engine.

They prevent sympathetic stimulation from whipping the heart into a frenzy.

And metoprolol is really the standout here, right?

Absolutely.

In post myocardial infarction care, metoprolol is the specific agent proven to prevent life threatening arrhythmias following a heart attack.

It just stabilizes all that irritable tissue.

It does.

But then you contrast that with esmolol, which is an IV only beta blocker reserved for emergencies or during surgery.

And esmolol's pharmacokinetics are completely unique.

They are.

It does not rely on the liver or the kidneys at all.

Wait, really?

How is it cleared?

It is rapidly metabolized by estruses floating right inside the erythrocytes, the red blood cells themselves.

Oh, wow.

So its half -life is just measured in minutes.

Exactly.

You turn the IV drip on, it works almost instantly, you turn it off, and it is gone.

As a result, it has virtually zero pharmacokinetic drug interactions.

That is incredibly useful.

Okay, let's shift to our third break, class three, the potassium channel blockers.

These drugs block the outward potassium current during repolarization.

So they don't touch the phase zero sodium spike.

Not primarily, no.

Instead, they massively prolong phase three repolarization and lengthen the tissue's effective refractory period.

They force the heart muscle to take a much longer pause before it is capable of firing again.

Right.

But remember that shadow we talked about earlier?

Prolonging phase three widens the action potential.

Which means a prolonged QT interval and the ever -present danger of torsades de pointes.

Yes.

And now we have to talk about amiodarone.

Oh, boy.

Amiodarone.

Amiodarone is a pharmacological beast.

I like to think of it as a shotgun approach.

Because it hits everything.

It really does.

It predominantly blocks potassium, but it actually hits sodium channels, calcium channels, and beta receptors all at once.

So it essentially has actions from all four Vaughan Williams classes.

Yes.

But because of its structure, it is a shotgun that leaves serious collateral damage.

It contains iodine.

Right.

It does.

It structurally mimics thyroxine, our thyroid hormone.

And its half -life is absolutely absurd.

I mean, it takes several weeks to clear from the body because it is highly lipophilic.

It loves fat.

Right.

So it distributes extensively into tissues and just sits there.

When a patient is on this long term,

the adverse effects are wild.

Because of the iodine, it can cause severe thyroid dysfunction.

Right.

Both hyper and hypothyroidism.

Exactly.

And because it accumulates deeply in tissues, it causes pulmonary fibrosis, which can be fatal.

It causes hepatotoxicity, optic neuritis, and it can literally deposit in the skin.

Turning it a physical blue -gray color.

Yes.

Blue -gray skin.

That is terrifying.

It is.

But here is the most baffling part.

Despite this massive list of toxicities, amiodarone is actually considered the least pro -rhythmic of the Class I and III drugs.

Wait, really?

It is a true clinical paradox.

It completely is.

It stretches the action potential significantly, but somehow has a very low incidence of torsades to point.

That's why it is used so frequently, despite the severe side effects.

It's incredibly effective for severe refractory arrhythmias.

Yeah.

Exactly.

Then you have drondarone.

The developer is essentially trying to build a better amiodarone by removing the iodine.

Okay, so no iodine means no thyroid issues.

Right.

Right.

But it comes with its own black box warning.

It is strictly contraindicated in patients with symptomatic heart failure or permanent atrial fibrillation.

Because it actually increases the risk of death.

Yeah, unfortunately.

We also have sotalol in this class.

Sotalol is unique because it is a non -selective beta blocker.

So that's a Class II mechanism.

But it also strongly blocks potassium channels, giving it Class III action.

And because of the serious risk of QT prolongation, initiating sotalol actually requires the patient to be admitted to the hospital.

Yes, for continuous EKG monitoring for several days.

Wow.

And the same strict protocol goes for dofetalide, right?

A pure potassium channel blocker limited entirely to inpatient initiation.

Exactly.

And finally, there is ebutylite, an IV -only drug that serves as the chemical treatment of choice for rapidly converting atrial flutter back to a normal sinus rhythm.

Okay, that brings us to our final formal group, Class IV, the calcium channel blockers.

Specifically verapamil and diltiezum.

But wait, I have a fundamental pushback question here.

Calcium channels are everywhere in the body, right?

Especially in blood vessels.

So why do these specific drugs primarily affect the heart's rhythm instead of just completely crashing the patient's blood pressure?

That is a great question.

And it all comes back to that brilliant concept of use dependence we saw with the sodium blockers.

Oh, okay.

Verapamil and diltiezum are non -dihydropyridine calcium blockers.

They bind almost exclusively to open, depolarized, voltage -sensitive calcium channels.

So they specifically target tissues that completely rely on calcium currents to fire.

Exactly.

Yeah.

Namely the SA and AV nodes.

Got it.

Because the AV node's conduction velocity is entirely dependent on calcium, these drugs are phenomenal at slowing electrical traffic through it.

This makes them primarily useful for treating atrial arrhythmias, like re -entrant supraventricular tachycardia.

Right.

Or slowing down a dangerously rapid ventricular response in atrial fibrillation.

And the side effects are essentially what you would expect from slowing the heart and relaxing vessels, bradycardia, hypotension, peripheral edema.

And you also have to carefully watch for major drug interactions because they inhibit the CYP3A4 liver enzyme.

Right.

Okay.

So that covers the Vaughan Williams map.

But the chapter finishes with a few critical outliers, the other antiarrhythmics that just do not fit the mold.

Starting with digoxin.

Digoxin operates on a completely different frequency.

It really does.

It inhibits the sodium -potassium ATPase pump.

This complex physiological cascade ultimately slows conduction velocity and prolongs the refractory period specifically in the AV node.

It is an old -school drug used for rate control in atrial fibrillation.

But there is a crucial clinical monitoring pearl here from the study questions.

Oh, the therapeutic index.

Digoxin has a notoriously narrow therapeutic index.

For atrial fibrillation, you are targeting a very specific serum trough concentration of just 1 .0 to 2 .0 nanograms per milliliter.

And if you go slightly above that, digoxin toxicity actually triggers ectopic ventricular beats.

Which means it can cause the exact fatal arrhythmias you are using it to prevent.

Exactly.

It's a very tight, tightrope.

Next, we have adenosine.

Given intravenously at high doses, it essentially hits the hard reset button on the AV node.

By radically decreasing conduction velocity and automaticity.

Right.

And the pharmacokinetics are staggering.

Its duration of action is only 10 to 15 seconds.

Wait, 10 to 15 seconds.

That's it.

That's it.

It is exceptionally fast.

The moment it enters the bloodstream, it is rapidly taken up by erythrocytes and endothelial cells.

Making it the absolute drug of choice for acute IV conversion of supraventricular tachycardias.

Yeah.

The patient experiences intense, brief flushing, chest pain, and hypotension.

But then it is entirely out of their system seconds later.

Amazing.

We also have magnesium sulfate.

Taking oral magnesium won't fix an arrhythmia, obviously.

But IV magnesium is the literal lifesaver, the definitive drug of choice for treating both digoxin -induced arrhythmias and the dreaded torsades de pointes.

Yes.

And finally, there is ranolazine.

It is normally classified as an anti -anginal drug for chest pain, but it has distinct antiarrhythmic properties.

Similar to mexilotine, it actually shortens repolarization, making it a valuable add -on option for patients with refractory arrhythmias.

So taking a step back, look at the journey we have just been on.

We started by understanding the basic, slow, inward leak of sodium and calcium in phase 4 that sparks a heartbeat.

And from there, we explored the incredibly intricate ways we can manipulate those exact sodium, potassium, calcium, and beta receptors to force a chaotic, short -circuiting heart back into a steady, reliable rhythm.

It really leaves you with a profound realization about the evolutionary trade -off of the heart's design.

Remean.

Well, think about it, long after this deep dive is over.

The very automaticity that allows our hearts to beat entirely independently, keeping us alive without us having to consciously think about it.

It is the exact same mechanism that makes the heart so vulnerable.

It is that precise independence that allows a single group of injured cells to go rogue and create chaotic, potentially fatal rhythms.

Wow.

It's a miraculous design, but an inherently fragile one.

What an incredible thought to end on.

If you're a student seeing this for the first time, you now have the conceptual map and the physiological why to navigate these complex drugs.

You're ready.

Consider this your last -minute review before the big exam.

On behalf of all of us here on the Last Minute Lecture team, we want to thank you for listening.

Best of luck on your pharmacology exams, and keep diving deep.